The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting

Özkaya, Abdullah; Alagöz, Cengiz; Garip, Rüveyde; Alkın, Zeynep; Perente, İrfan; Yazıcı, Ahmet; Taşkapili, Mühittin

doi:10.1038/eye.2016.71

Cited by 19 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Before the era of anti-vascular endothelial growth factor treatment, visual loss prevention was only achieved in a limited number of patients despite the use of different treatment modalities [ 3 4 5 6 7 ]. Bevacizumab, ranibizumab, and finally aflibercept treatments have led to conservation of baseline visual acuity (VA) in the vast majority of patients and significantly increased VA in approximately one-third of patients [ 8 9 10 11 12 ]. Multicenter studies have shown that ranibizumab treatment can prevent significant visual loss in up to 95% of patients, and VA improvement can be achieved in up to 40% of the patients [ 13 14 ].…”

mentioning

confidence: 99%

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience

Özkaya

Alkın

Togac

et al. 2017

Korean J Ophthalmol

View full text Add to dashboard Cite

PurposeTo evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clinical setting.MethodsThe records of nAMD patients who were treated with ranibizumab between January 2010 and June 2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcome measures were change in best-corrected visual acuity, central retinal thickness, and visit and injection numbers.ResultsForty-four eyes of 37 patients were included. Mean best-corrected visual acuity decreased from 0.82 ± 0.69 to 1.11 ± 0.65 logarithm of minimal angle of resolution after 5 years. Twenty-four eyes (54.5%) had visual acuity loss ≥3 lines, and 20 eyes (45.5%) had stable or improved vision (loss <3 lines, remained stable, or gained ≥1 line) at month 60. The mean total number of visits was 25.3 ± 5.8 (range, 14 to 42), and the mean total number of injections was 12.6 ± 6.4 (range, 3 to 26) at month 60.ConclusionsHalf of the ranibizumab-treated nAMD patients maintained their vision during the 5 years of follow-up. Visit and injection numbers were found to be lower than in prospective studies, reflecting a real world clinical practice.

show abstract

mentioning

confidence: 99%

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience

Özkaya

Alkın

Togac

et al. 2017

Korean J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…[ 22 ] ICGA has also been shown to be useful in the evaluation of neovascular AMD patients who were poor responders to ranibizumab treatment and were subsequently diagnosed with having PCV in their revised diagnosis. [ 23 ] Recent studies have proposed the use of ICGA in the classification of PCV and have classified PCV into 2 angiographic subtypes. [ 24 ] Polypoidal CNV (type 1 PCV) is characterized by the presence of feeder and draining vessels on ICGA and is reported to show better visual improvement in response to anti-VEGF therapy but has poorer response to verteporfin photodynamic therapy (vPDT).…”

Section: Diagnosis Of Pcvmentioning

confidence: 99%

Current management strategy of polypoidal choroidal vasculopathy

Lai

2018

Indian J Ophthalmol

View full text Add to dashboard Cite

Polypoidal choroidal vasculopathy (PCV) is a retinal disorder commonly found in Asians presenting as neovascular age-related macular degeneration and is characterized by serous macular detachment, serous or hemorrhagic pigment epithelial detachment, subretinal hemorrhage, and occasionally visible orange-red subretinal nodular lesions. PCV is diagnosed using indocyanine green angiography (ICGA), and the lesions appear as polypoidal aneurysmal vascular lesions with or without abnormal branching vascular network. Although ICGA remains the gold standard for the diagnosis of PCV, various imaging modalities have also facilitated the diagnosis and monitoring of PCV. Recent advances in imaging technology including the use of high resolution spectral domain optical coherence tomography (OCT) and OCT angiography have provided new insights on the pathogenesis of PCV, suggesting a link between PCV and pachychoroid spectrum of macular disorders. With the evolving understanding on the pathogenesis and clinical characteristics of PCV, different therapeutic options have been proposed. These include intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy, combination therapy with anti-VEGF and verteporfin photodynamic therapy, and thermal laser photocoagulation. In recent years, major multi-center randomized clinical trials such as EVEREST, EVEREST II, and PLANET studies have been conducted to compare the efficacy and safety of various treatment options for PCV. This review aims to summarize the results of recent literature, clinical trials and studies to provide an update on the management options of PCV. An overall management strategy for PCV will also be proposed.

show abstract

“…[7][8][9] In a cross-sectional, retrospective study, most patients diagnosed with nAMD who demonstrated a poor response to ranibizumab had atypical nAMD, with the majority having PCV. 10 These results suggest a need for novel treatments for nAMD that require less-frequent administration (decreasing the burden of treatment) and that are effective in atypical subtypes of nAMD lesions.…”

Section: Introductionmentioning

confidence: 97%

Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States

Kunimoto¹,

Ohji²,

Maturi³

et al. 2019

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE: To evaluate comparability of abicipar pegol (abicipar) effects in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in Japan and the United States. PATIENTS AND METHODS: Phase 2, multicenter, randomized, double-masked, 20-week studies (BAMBOO, Japan; CYPRESS, United States). Patients (n = 25 each study) received three monthly intravitreal injections of abicipar 1 mg or 2 mg or five monthly intravitreal injections of ranibizumab 0.5 mg. RESULTS: Mean best-corrected visual acuity change from baseline at week 16 (primary endpoint) for abicipar 1 mg, abicipar 2 mg, and ranibizumab was +7.8 letters, +8.9 letters, and +17.4 letters (BAMBOO); +4.4 letters, +10.1 letters, and +15.2 letters (CYPRESS). Mean central retinal thickness change from baseline was −187.3 μm, −196.5 μm, and −230.4 μm (BAMBOO); −106.5 μm, −112.8 μm, and −124.4 μm (CYPRESS). Uveitis or vitritis was reported in three abicipar-treated patients. CONCLUSION: Abicipar demonstrated extended duration of effect and safety that were comparable between Japanese and non-Japanese patients with nAMD. Abicipar effectively treated Japanese patients with polypoidal choroidal vasculopathy.

show abstract

The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting

Cited by 19 publications

References 28 publications

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience

Current management strategy of polypoidal choroidal vasculopathy

Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States

Contact Info

Product

Resources

About